Stay updated on Effect of Nintedanib on ECM Biomarkers in IPF Clinical Trial

Sign up to get notified when there's something new on the Effect of Nintedanib on ECM Biomarkers in IPF Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Effect of Nintedanib on ECM Biomarkers in IPF Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    Revision tag updated from v3.4.2 to v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-12T19:35:44.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    Revision updated from v3.4.1 to v3.4.2; no substantive content or layout changes are visible in the screenshots. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-12T00:02:46.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    Footer revision tag updated from v3.4.0 to v3.4.1. No changes to study information or navigation.
    Difference
    0.0%
    Check dated 2026-02-04T23:47:41.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    Added Show glossary toggle; updated metadata labels to include 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data' with Revision set to v3.4.0, and removed the previous labels 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and Revision: v3.3.4.
    Difference
    0.1%
    Check dated 2026-01-28T21:37:16.000Z thumbnail image
  7. Check
    63 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.3.4, replacing the previous Revision: v3.3.3.
    Difference
    0.0%
    Check dated 2026-01-14T04:22:25.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    The page now includes expanded Locations with new site entries across Alabama, Connecticut, Florida, Minnesota, Missouri, Ohio, Virginia, New South Wales, South Australia, and Victoria. The HHS Vulnerability Disclosure link was removed and the revision is updated to v3.3.3.
    Difference
    0.7%
    Check dated 2025-12-23T20:56:26.000Z thumbnail image

Stay in the know with updates to Effect of Nintedanib on ECM Biomarkers in IPF Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Effect of Nintedanib on ECM Biomarkers in IPF Clinical Trial page.